Related Experiment Video

Updated: Jul 16, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering

A Zambon1, B G Brown, J E Hokanson

  • 1Department of Medicine, University of Washington, Seattle, WA 98195-6426, USA.

Journal of Internal Medicine
|April 6, 2006
PubMed

Insights

Different genetic forms of dyslipidaemia influence response to lipid-lowering therapy. Familial hypercholesterolaemia (FH) patients require aggressive LDL reduction, while familial combined hyperlipidaemia (FCHL) and elevated Lp(a) patients benefit from therapies targeting small, dense LDL particles.

Area of Science:

  • Cardiology
  • Genetics
  • Metabolic Disorders

Background:

  • Lipid-lowering therapy (LL-Rx) is crucial for managing coronary artery disease (CAD).
  • Individual responses to LL-Rx for CAD vary significantly.
  • Genetic dyslipidaemias contribute to varied responses in CAD patients.

Purpose of the Study:

  • To investigate the impact of three genetic dyslipidaemia forms on angiographic response to LL-Rx.
  • To analyze the contribution of elevated plasma apo B, familial hypercholesterolaemia (FH), familial combined hyperlipidaemia (FCHL), and elevated Lp(a) to LL-Rx outcomes.
  • To determine if specific genetic dyslipidaemia types necessitate tailored LL-Rx strategies.

Main Methods:

  • Selected 51 men with premature CAD and elevated plasma apo B based on family lipid phenotypes.
  • Administered conventional (diet +/- colestipol) or intensive LL-Rx (niacin or lovastatin plus colestipol) for 2 years.
  • Assessed clinical parameters and CAD severity (coronary stenosis) before and after treatment.

Main Results:

  • Coronary stenosis regression was significantly influenced by LL-Rx effectiveness, genetic dyslipidaemia type, and their interaction.
  • Significant regression of coronary stenosis was observed only in patients with FCHL and elevated Lp(a).
  • CAD progression was notably slowed in patients with FH.

Conclusions:

  • Distinct genetic dyslipidaemia forms are associated with differential angiographic outcomes during LL-Rx.
  • Tailored lipid-lowering strategies may be required for different genetic dyslipidaemia types.
  • FH patients with buoyant LDL need aggressive LDL reduction; FCHL/elevated Lp(a) patients with dense LDL require LDL reduction plus therapies targeting small, dense LDL particles.
Abstract

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...